Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 at Increased Risk for Severe RSV Over Two RSV Seasons ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results